• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Molecular Diagnostics Market Report: 2011 Edition Product Image

Molecular Diagnostics Market Report: 2011 Edition

  • Published: June 2011
  • Region: Global
  • 43 Pages
  • Koncept Analytics

FEATURED COMPANIES

  • Bayer AG
  • Gen-Probe
  • QIAGEN
  • Roche Holdings AG
  • MORE

Molecular diagnostics refers to the technique of identifying the presence of any infection or disease, gene mutations, or any type of antigens attacking the body, with the help of the genetic and protein activity patterns of the body. Primarily, the molecular diagnostic tests are performed for three purposes: diagnosis of the infectious diseases, genetic identification and the diagnosis of genetic diseases. Currently, molecular diagnostics represent a small share in the in-vitro diagnostics market, but it offers immense opportunities for growth in future and therefore, is likely to drive the in-vitro diagnostics market in the foreseeable future.

Diagnostic tests play an important role in helping the physicians in making decisions, as it has been found that around 80% of the physicians’ decisions are based on the diagnostic reports. With the advent of faster and more accurate molecular tests, coupled with the better sensitivity and specificity of the molecular tests, there has been a shift from the traditional testing methods towards the molecular diagnostic tests.

Presently, the molecular diagnostic market is growing on the back of oncology and the infectious disease READ MORE >

1. Introduction
1.1 In Vitro Diagnostics: Industry Overview
1.2 Molecular diagnostics

2. Global In-Vitro Diagnostics Market
2.1 Market Value & Growth Rate
2.2 Key Segments

3. Global Molecular Diagnostics Market
3.1 Market Size
- Market Share by Segments
- Market Share by Applications
3.2 Market Segments
3.2.1 Cancer
3.2.2 HPV (Human Papillomavirus)
3.2.3 Theranostics

4. Market Dynamics
4.1 Opportunities for Growth
4.1.1 CT/GC Market
4.1.2 HPV Tests
4.1.3 Hospital Acquired Infections (HAI)
4.1.4 Influenza Molecular Tests
4.1.5 Growth of Companion Diagnostic Tests
4.1.6 Growth in the Emerging Markets
4.2 Growth Drivers
4.2.1 Rapidly ageing Population
4.2.2 Shift towards Molecular Diagnostics
4.2.3 Rising Health Care Costs
4.2.4 High returns on investment (ROI)

5. Key Issues
5.1 Lack of Skilled Workforce
5.2 Complex Reimbursement Conditions

6. Competitive Landscape
6.1 Competitive Overview
6.2 Market Share
6.3 Financial Comparison

7. Company Profiles

7.1 Roche Holdings AG
- Company Overview
- Key Financials
- Business Strategies
- Innovation to Tap Potential of Modern Science
- Providing Personalized Healthcare
- Focus on Unmet Medical Needs
- Increase in Research and Development

7.2 Gen-Probe
- Company Overview
- Key Financials
- Business Strategies
- Expansion through Acquisitions
- Increasing Commitment to Quality
- Focus on Innovation
- Marketing Strategy

7.3 QIAGEN
- Company Overview
- Key Financials
- Business Strategies
- Wide Geographical Presence
- Focus on Strategic Objectives
- Increasing Investment in Research and Development

7.4 Bayer AG
- Company Overview
- Key Financials
- Business Strategies
- Obtaining Leadership in all Segments
- Health Care Strategy

8. Market Outlook
8.1 Market Forecast
8.2 Forecast Methodology
8.2.1 Dependent and Independent Variables
8.2.2 Correlation Analysis
8.2.3 Regression Analysis

List of Charts

- IVD Market – Segments by Technology
- Molecular Diagnostcs – Traditional Process
- Main Purposes of Molecular Diagnostics
- Global IVD Market Size (2002-2009)
- Global IVD Market-by Clinical Segments (2009)
- Global IVD Market-Share by Segments (2014)
- Global Molecular Diagnostics Equipment Market (2003-2010E)
- Global Molecular Diagnostics Market-Share by Segments (2008)
- Global Molecular Diagnostics Market-Share by Application Areas (2010)
- Global Molecular Diagnostic Testing Market for Cancer (2001-2012)
- Global HPV Market-Value Share by Region (2009)
- Chinese HPV Market-Share by Companies (2009)
- Global Molecular Diagnostic Testing Market for Theranostics (2002-2012)
- CT/GC Revenue Share-by Major Companies (2007-2009)
- Ageing Population Worldwide (age>65) 2005-2015
- Cancer Costs-by Type (2010 & 2020)
- Worldwide Molecular Diagnostic Market-Share by Companies (2010)
- DNA Based Diagnostic Test Equipment Market-Share by Companies (2009)
- Roche Revenue (2006-2010)
- Roche Revenue-Share by Segments (2010)
- Roche/Genetech-Share of Projects in Research & Early Phase (Jan 2011)
- Roche and Genetech-Share of Projects in Phase III (Jan ‘11)
- Gen-Probe Revenue (2006-2010)
- Gen-Probe Revenue-by Sources (2010)
- QIAGEN Revenue (2006-2010)
- QIAGEN Revenue-Share by Source of Revenue (2010)
- QIAGEN Revenue-Share by Geographic Segments (2010)
- Bayer AG Revenue (2006-2010)
- Bayer AG Revenue-Share by Segments (2010)
- Global Molecular Diagnostics Market Forecast (2010 – 2014E)

List of Tables

- Top 10 Global IVD Market (2008 and 2015)
- National Limitation Amount for CPT Codes (2009-2010)
- US Molecular Testing Platforms-by Major Companies
- Financial Position of Key Players (2010)
- Dependent & Independent Variables (2003 – 2010)
- Correlation Matrix
- Model Summary – Coefficient of Determination
- Regression Coefficients Output

- Roche Holdings AG
- Gen-Probe
- QIAGEN
- Bayer AG

Note: Product cover images may vary from those shown

ALSO AVAILABLE

RELATED PRODUCTS

Our Clients

Our clients' logos